Halozyme Therapeutics, Author at V3 Media

U.S. FDA Approves RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) Co-Formulated with Halozymes ENHANZE® Technology for the Treatment of Advanced Head and Neck Cancer

Approval extends RYBREVANT FASPRO’s well-established, dual-targeted benefit beyond lung cancer , /PRNewswire/ — Halozyme Therapeutics, Inc.…